Applied Biosystems, Qiagen Ink PCR Licensing Deal

Applied Biosystems has granted a license to Qiagen under an expanded PCR license program that Applied Biosystems launched in June, the companies announced this week.

ABI's expanded program includes patents for real-time PCR and other PCR-related technologies not licensed under its previous PCR licensing program. Specifically, the program includes a license to foundational patents, the TaqMan assay, and the Dye-Intercalation assay method.

Financial terms of the arrangement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.